Interim [ 18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab

Journal of Clinical Oncology

Volumn 30, Issue 2, 2012, Pages 184-190

  Safar, Violaine ^a   Dupuis, Jehan ^a   Itti, Emmanuel ^a   Jardin, Fabrice ^c   Fruchart, Christophe ^b   Bardet, Stéphane ^b   Véra, Pierre ^c   Copie Bergman, Christiane ^a   Rahmouni, Alain ^a   Tilly, Hervé ^c   Meignan, Michel ^a   Haioun, Corinne ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b CENTRE FRANÇOIS BACLESSE   (France)

^c CENTRE HENRI BECQUEREL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; SCINTISCANNING;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84855610324     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.2648     Document Type: Article

References (26)

1. [No authors listed]: A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
2. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000 (Pubitemid 30082188)
3. Haioun C, Itti E, Rahmouni A, et al: [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: An early prognostic tool for predicting patient outcome. Blood 106:1376-1381, 2005 (Pubitemid 41129604)
4. Jerusalem G, Beguin Y, Fassotte MF, et al: Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 85: 613-618, 2000 (Pubitemid 30450941)
5. Spaepen K, Stroobants S, Dupont P, et al: Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 13:1356-1363, 2002
6. Kostakoglu L, Coleman M, Leonard JP, et al: PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 43:1018-1027, 2002 (Pubitemid 34847924)
7. Mikhaeel NG, Hutchings M, Fields PA, et al: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514-1523, 2005 (Pubitemid 41222425)
8. Dupuis J, Itti E, Rahmouni A, et al: Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: Integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 20:503-507, 2009
9. Fruchart C, Reman O, Le Stang N, et al: Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: A prospective comparative study. Leuk Lymphoma 47:2547-2557, 2006 (Pubitemid 44932645)
10. Cheson BD: Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844-1854, 2011
11. Han HS, Escalón MP, Hsiao B, et al: High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 20: 309-318, 2009
12. Pregno P, Chiappella A, Bello M, et al: Interim 18-FDG-positron emission tomography/computed tomography (PET) failed to predict different outcome in diffuse large b-cell lymphoma (DLBCL) patients treated with rituximab-chop. Blood 114:99, 2009 (abstr 99)
13. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
14. Pfreundschuh M, Trümper L, Osterborg A, et al: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379-391, 2006
15. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007 (Pubitemid 46348180)
16. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
17. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al: 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma: Comparison with CT. Leuk Lymphoma 39:543-553, 2000 (Pubitemid 32162393)
18. Itti E, Lin C, Dupuis J, et al: Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 50:527-533, 2009
19. Lin C, Itti E, Haioun C, et al: Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 48:1626-1632, 2007 (Pubitemid 47572710)
20. Gisselbrecht C, Lepage E, Molina T, et al: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20:2472-2479, 2002 (Pubitemid 34525732)
21. Terasawa T, Lau J, Bardet S, et al: Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large b-cell lymphoma: A systematic review. J Clin Oncol 27:1906-1914, 2009
22. Yoo C, Lee DH, Kim JE, et al: Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 90: 797-802, 2011
23. Meignan M, Gallamini A, Haioun C, et al: Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk Lymphoma 51:2171-2180, 2010
24. Herrmann K, Wieder HA, Buck AK, et al: Early response assessment using 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13:3552-3558, 2007 (Pubitemid 46955115)
25. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al: SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37-43, 2011
26. Moskowitz CH, Schöder H, Teruya-Feldstein J, et al: Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28:1896-1903, 2010